PPT-Peginterferon alfa-2a versus

Interferon alfa2a Phase 3 Treatment Naïve Chronic HCV Zeuzem S et al N Engl J Med 2000343166672 Source Zeuzem S et al N Engl J Med 2000343166672 Peginterferon alfa2a versus Interferon alfa. Genotype . 1 . (. Viral . Relapsers. ). PROMISE . Trial. Phase . 3. Treatment. . Experienced. Forns. X. , . et al. . Gastroenterology. 2014;146:1669-79.e3.. Source: . Forns. X. , et al. Gastroenterology. 2014;146:1669-79.e3.. Treatment –Experienced Genotype . 1 . ASPIRE Trial. Phase . 3. Treatment. . Experienced. Z. euzem. S. , . et al. . Gastroenterol. . 2014;146:430-41.. Source: . Zeuzem. S. , et al. . Gastroenterol. alfa-2a . versus. . Interferon . alfa-2a. Phase 3. Treatment. . Naïve, Chronic HCV. Zeuzem. S, et al. N . Engl. J Med. 2000;343:1666-72.. Source: . Zeuzem. S, . et al. . N Engl J Med. 2000;343:1666-72.. versus. . Interferon alfa-2b + Ribavirin . Phase 3. Treatment. . Naïve, Chronic HCV. Manns. . MP, et. al. Lancet. 2001;358:958-65. Peginterferon alfa-2b + Ribavirin . versus . Interferon alfa-2b + Ribavirin . Pegasys. ). Prepared by: David Spach, MD & H. Nina Kim, MD. Last Updated: February . 14, . 2014. Background and Dosing. Peginterferon alfa-2a (. Pegasys. ). Peginterferon alfa-2a (. Pegasys. ). Summary. Phase 3. Treatment. . Naïve, Chronic HCV. McHutchison. . JG, et al. N . Engl. J Med. 1998;339:1485-92.. I. nterferon . alfa-. 2b . +/- Ribavirin for Chronic HCV. Study . Outline. Study. -. . Randomized, double-blinded, placebo controlled, phase 3 trial. with PEG + RBV in Genotype 1. SPRINT. -1. Phase . 2. Treatment. . Naïve. Kwo. PY, et al. Lancet. 2010;376:705-16.. Source: . Kwo PY, et al. Lancet. 2010;376:705-16. .. Boceprevir . for Treatment-Naïve HCV Genotype 1. Flat versus Weight-Based Ribavirin Dosing. Phase . 3. Treatment. . Naïve, Chronic HCV. Jacobson IM, et. al. Hepatology. 2007;46:971-81.. *Weight-based . ribavirin. dosing: < 65 kg: 800 mg/. d. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . . alfa. -. 2b. . + RBV vs. . Peginterferon alfa-. 2a. . + RBV. IDEAL . STUDY. Phase 3, Treatment Naïve. Treatment. . Naïve, Chronic HCV. McHutchison. JG, et. al. N . Engl. J Med. 2009;361:580-93. . Molinuevo. , Craig Ritchie, . Miia. . Kivipelto. tribeka.org. @. TRIBEKAplatform. The. . TriBEKa. . imaging. . consortium. Barcelona-Edinburgh-. Karolinska. The . mission. of the consortium is to generate an . Mark Sulkowski, MD. Professor of Medicine. Johns Hopkins University. Baltimore Maryland 21212. Case . 57 . yo. woman with genotype 1a and bridging fibrosis. PROVE-1 study – treated with TVR x 12 . versus. Interferon alfa-2b + Ribavirin. Phase 3. Treatment. . Naïve, Chronic HCV. Fried MW, . et al. N . Engl. J Med. . 2002;347:975-. 8. 2. .. Peginterferon +/- Ribavirin versus Interferon + . Ribavirin. ID . : . DB00008 . Protein average . weight : . 60000.0000. . Half life : . Terminal half life is 80 hours (range 50 to 140 hours). . . Description. :. . Human interferon 2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched .